|
CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance). |
|
|
Honoraria - Astellas Scientific and Medical Affairs Inc; LSK Biopharma; Merck Sharp & Dohme |
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; LSK Biopharma; Merck |
Research Funding - Boston Biomedical; Lilly/ImClone; Merck; Roche/Genentech |
Travel, Accommodations, Expenses - Lilly |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Roche |
Travel, Accommodations, Expenses - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Roche |
|
|
No Relationships to Disclose |
|
|
|
Patents, Royalties, Other Intellectual Property - Roche |
|
|
Employment - Ventana Medical Systems |
Patents, Royalties, Other Intellectual Property - Ventana Medical Systems |
|
|
|
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Roche |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche |
Patents, Royalties, Other Intellectual Property - Roche |
|
|
Stock and Other Ownership Interests - illumina |
Honoraria - American Society of Clinical Oncology; Imedex |
Consulting or Advisory Role - EMD Serono; Roche; Roche/Genentech; Ventana Medical Systems |
Travel, Accommodations, Expenses - ventana medical systems |